News
Magenta Therapeutics to merge with Dianthus Therapeutics and advance DNTH 103 complement inhibitor
Magenta Therapeutics, Inc. and Dianthus Therapeutics, Inc. , a privately-held, clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.
Upon completion of the merger, the combined company is expected to operate under the name Dianthus Therapeutics, Inc. and trade on the Nasdaq under the ticker symbol “DNTH”.
Type: industry
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
